Ascendis Pharma A/S Partners with Orsini to Improve YORVIPATH® Access for Hypoparathyroidism Patients
- Ascendis Pharma A/S partners with Orsini to improve access to YORVIPATH® for chronic hypoparathyroidism patients in the U.S.
- The collaboration aims to enhance patient care and streamline access to YORVIPATH®, a 24-hour hormone release therapy.
- Ascendis Pharma is committed to advancing its portfolio in rare diseases, showcasing ongoing innovation in patient care.
Ascendis Pharma Partners with Orsini to Enhance Access to YORVIPATH® for Chronic Hypoparathyroidism Patients
Ascendis Pharma A/S has established a significant partnership with Orsini, a recognized leader in pharmacy solutions for rare diseases and gene therapies. This collaboration aims to facilitate access to YORVIPATH® (palopegteriparatide), an FDA-approved treatment specifically designed for adults suffering from chronic hypoparathyroidism. This rare endocrine disorder affects roughly 70,000 individuals across the United States, marked by insufficient levels of parathyroid hormone, which can lead to debilitating symptoms such as chronic pain, muscle cramps, cataracts, bone damage, and kidney stones. Through this partnership, Ascendis Pharma seeks to ensure that patients have streamlined access to this innovative therapy, which provides continuous hormone release over a 24-hour period.
YORVIPATH® is not only approved in the United States but also in the European Union, the United Kingdom, and the European Economic Area, showcasing its global relevance. The partnership with Orsini aligns with Ascendis Pharma's mission to enhance the quality of life for patients with rare diseases. Orsini's Chief Growth Officer, Darin DeCarlo, expresses enthusiasm for incorporating YORVIPATH into their endocrinology portfolio, underscoring the company’s commitment to serving those affected by rare conditions. Orsini's extensive history, dating back to 1987, positions it well to provide comprehensive services that facilitate access to advanced medicines, thus embodying the motto "No Patient is Left Behind™."
The collaboration is set against a backdrop of increasing recognition for Orsini as a distinguished Rare Disease Pharmacy Center of Excellence. With multiple accreditations from reputable organizations such as The Joint Commission and URAC, Orsini is equipped to offer specialized patient services, home infusion, and nursing support to ensure effective treatment delivery. This partnership not only strengthens Ascendis Pharma's commitment to rare disease management but also enhances patient care through Orsini’s established infrastructure and dedication to collaboration with biopharma, providers, and payors.
In addition to the focus on YORVIPATH®, Ascendis Pharma continues to explore avenues for advancing its portfolio in rare diseases, signaling an ongoing commitment to innovation in patient care. The partnership with Orsini stands as a testament to Ascendis Pharma's proactive approach to meeting the needs of patients with complex health challenges. For further inquiries about Orsini's services or YORVIPATH®, interested parties can reach out to them directly or visit their website.